OrbiMed's Stake in Corvus Pharmaceuticals Diluted to 10.3% Following Recent Public Offering

summarizeSummary

OrbiMed Advisors and OrbiMed Capital GP V LLC reported a decrease in their beneficial ownership of Corvus Pharmaceuticals to 10.3% due to the company's recent public offering.

check_boxKey Events

• Ownership Percentage Reduced

  OrbiMed's beneficial ownership decreased to 10.3% of Corvus Pharmaceuticals' common stock, down from a previous undisclosed percentage by more than 1%.

• Impact of Public Offering

  The reduction in percentage ownership is a direct result of the company's underwritten public offering of 7,900,677 shares completed on January 23, 2026, which increased the total outstanding shares.

• Lock-Up Agreement Disclosed

  A 45-day lock-up agreement was entered into by certain directors and officers, including an OrbiMed member, restricting share sales following the offering.

auto_awesomeAnalysis

This Schedule 13D/A filing by institutional investor OrbiMed Advisors and OrbiMed Capital GP V LLC updates their beneficial ownership in Corvus Pharmaceuticals. Their stake has been diluted to 10.3% of outstanding shares, a decrease of more than 1%, as a direct result of the company's underwritten public offering completed on January 23, 2026. While OrbiMed did not sell shares, the increase in total outstanding shares from the offering reduced their proportional ownership. This filing confirms the dilutive impact of the recent capital raise on major shareholders. Additionally, a lock-up agreement was disclosed, restricting sales by certain directors and officers, including an OrbiMed member, for 45 days post-offering.